Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure

Journal of the National Cancer Institute

Volumn 89, Issue 7, 1997, Pages 480-487

  Dedrick, Robert L ^a,c   Flessner, Michael F ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE;

CLINICAL TRIAL; DRUG EXPOSURE; DRUG MIXTURE; DRUG PENETRATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; MATHEMATICAL MODEL; MOLECULAR MODEL; OVARY CANCER; REVIEW; TISSUE DISTRIBUTION;

EID: 0030909491     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.7.480     Document Type: Review

References (61)

1. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11.
2. Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990;26:755-62.
3. Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801-5.
4. Markman M, Blessing JA, Major F, Manetta A. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study. Gynecologic Oncol 1993;50:191-5.
5. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
6. Dedrick RL, Flessner MF, Collins JM, Schultz JS. Is the peritoneum a membrane? Am Soc Artificial Internal Organs J 1982;5:1-8.
7. Collins JM, Dedrick RL. Pharmacokinetics of anticancer drugs. In: Chabner BA, editor. Pharmacologic principles of cancer treatment. Philadelphia: Saunders, 1982:77-99.
8. Dedrick RL. Interspecies scaling of regional drug delivery. J Pharm Sci 1986;75:1047-52.
9. Flessner MF. Peritoneal transport physiology: insights from basic research. J Am Soc Nephrol 1991;2:122-35.
10. Flessner MF, Dedrick RL. Intraperitoneal chemotherapy. In: Gokal R, Nolph KD, editors. The textbook of peritoneal dialysis. 1st ed. Dordrecht: Klewer, 1994:769-89.
11. Gupta E, Wientjes MG, Au JL. Penetration kinetics of 2′,3′-dideoxyinosine in dermis is described by the distributed model. Pharm Res 1995;12: 108-12.
12. Jirtle RL. Chemical modification of tumour blood flow. Int J Hyperthermia 1988;4:355-71.
13. Jain RK. Determinants of tumor blood flow: a review Cancer Res 1988; 48:2641-58.
14. Collins JM, Dedrick RL. Flessner MF, Guarino AM. Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: experimental observations and distributed modeling. J Pharm Sci 1982;71: 735-8.
15. Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients Am J Physiol 1985;248(3 Pt 2):F425-35.
16. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49;1989:3380-4.
17. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389-94.
18. Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 1991;51: 4347-54.
19. Wientjes MG, Dalton JT, Badalament RA, Wang RC, Hassan F, Au JL. Penetration of mitomycin C in human bladder. Cancer Res 1993;53: 3314-20.
20. Wientjes MG, Badalament RA, Au JL. Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol 1996;37:539-46.
21. Flessner MF. Small-solute transport across specific peritoneal tissue surfaces in the rat. J Am Soc Nephrol 1996;7:225-33.
22. Rubin J, Jones Q, Planch A, Rushton F, Bower JD. The importance of the abdominal viscera to peritoneal transport during peritoneal dialysis in the dog. Am J Med Sci 1986;292:203-8.
23. Rubin J, Jones Q, Planch A, Bower JD. The minimal importance of the hollow viscera to peritoneal transport during peritoneal dialysis in the rat. ASAIO Trans 1988;34:912-5.
24. Fox SD, Leypoldt JK, Henderson LW. Visceral peritoneum is not essential for solute transport during peritoneal dialysis. Kidney Int 1991;40:612-20.
25. Flessner MF, Dedrick RL. Role of the liver in small-salute transport during peritoneal dialysis. J Am Soc Nephrol 1994;5:116-20.
26. Levitt MD, Kneip JM, Overdahl MC. Influence of shaking on peritoneal transfer in rats. Kidney Int 1989;35:1145-50.
27. Rippe B, Zakaria ER, Carlsson O. Do visceral stagnant films limit the peritoneal exchange of small solutes [abstract]. Peritoneal Dialysis Int 1996;16 Suppl 2:S11.
28. Sagar SM, Klassen GA, Barclay KD, Aldrich JE. Tumour blood flow: measurement and manipulation for therapeutic gain. Cancer Treat Rev 1993;19:299-349.
29. Zlotecki RA, Baxter LT, Boucher Y, Jain RK. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res 1995;50:419-43.
30. Ward KA, Jain RK. Response of tumours to hyperglycaemia: characterization, significance and role in hyperthermia. Int J Hyperthermia 1988;4: 223-50.
31. Sevick EM, Jain RK. Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia. Cancer Res 1988;48:1201-7.
32. Scheim DE, Lin JY. Glucose effects in an ovarian cancer protocol of exceptional activity. Med Hypotheses 1993;40:235-44.
33. Gutman RA, Nixon WP, McRae RL, Spencer HW. Effect of intraperitoneal and intravenous vasoactive amines on peritoneal dialysis: study in anephric dogs. Trans Am Soc Artif Intern Organs 1976;22:570-4.
34. Henderson LW, Kintzel JE. Influence of antidiuretic hormone on peritoneal membrane area and permeability. J Clin Invest 1971;50:2437-43.
35. Hare HG, Valtin H, Gosselin RE. Effect of drugs on peritoneal dialysis in the dog. J Pharmacol Exp Ther 1964;145:122-9.
36. Lindner P, Heath D, Howell S, Naredi P, Hafstrom L. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. Clin Cancer Res 1996;2:311-7.
37. Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol 1985;248(1 Pt 2):H26-32.
38. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Physiol Rev 1994;74:163-219.
39. Chary SR, Jain RK. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc Natl Acad Sci U S A 1989;86:5385-9.
40. Berk DA, Yuan F, Leunig M, Jain RK. Fluorescence photobleaching as a noninvasive probe of interstitial transport in tumor tissue [abstract]. Ann Biomed Engr 1995;23 Suppl 1:S52.
41. Flessner MF. Osmotic barrier of the parietal membrane. Am J Physiol 1994;267(5 Pt 2):F861-70.
42. Stelin G, Rippe B. A phenomenological interpretation of the variation in dialysate volume with dwell time in CAPD. Kidney Int 1990;38:465-72.
43. Flessner MF, Schwab A. Pressure threshold for fluid loss from the peritoneal cavity. Am J Physiol 1996;270(2 Pt 2):F377-90.
44. Yuan F, Dellian M, Fukamura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in the human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995;55:3752-6.
45. Roh HD, Boucher Y, Kainicki S, Buchsbaum R, Bloomer WD, Jain RK. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 1991;51:6695-8.
46. Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW 2d, Madara K, et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res 1993;53:2204-7.
47. Butler TP, Grantham FH, Gullino PM. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res 1975;35(11 Pt 1): 3084-8.
48. Flessner MF, Dedrick RL, Reynolds JC. Bidirectional peritoneal transport of immunoglobulin in rats: tissue concentration profiles. Am J Physiol 1992;263(1 Pt 2):F15-32.
49. Flessner MF, Dedrick RL. Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration and intraperitoneal solution osmolality. Cancer Res 1994;54:4376-84.
50. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal taxol: a Gynecological Oncology Group study. J Clin Oncol 1992;10:1485-91.
51. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995;13: 2961-7.
52. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993;15:141-7.
53. Keshaviah P, Emerson PF, Vonesh EF, Brandes JC. Relationship between body size, fill volume, and mass transfer area coefficient in peritoneal dialysis. J Am Soc Nephrol 1994;4:1820-6.
54. Brandes JC, Packard WJ, Watters SK, Fritsche C. Optimization of dialysate flow and mass transfer during automated peritoneal dialysis. Am J Kidney Dis 1995;25:603-10.
55. Schoenfeld P, Diaz-Buxo J, Keen M, Gotch FA. The effect of body position (P), surface area (BSA), and intraperitoneal exchange volume (Vip) on the peritoneal transport constant (KoA) [abstract]. J Am Soc Nephrol 1993;4: 416.
56. Miller JH, Gipstein R, Margules R, Schwartz M, Rubini ME. Automated peritoneal dialysis: analysis of several methods of peritoneal dialysis. Trans Am Soc Artif Intern Organs 1966;12:98-105.
57. Raja RM, Kramer MS, Rosenbaum JL. Recirculation peritoneal dialysis with sorbent Redy cartridge. Nephron 1976;16:134-42.
58. Stephen RL, Atkin-Thor E, Kolff WJ. Recirculating peritoneal dialysis with subcutaneous catheter. Trans Am Soc Artif Intern Organs 1976;22: 575-85.
59. Warden GD, Maxwell JG, Stephen RL. The use of reciprocating peritoneal dialysis with subcutaneous peritoneal catheter in end-stage renal failure in diabetes mellitus. J Surg Res 1978;24:495-500.
60. Finkelstein FO, Kliger AS. Enhanced efficiency of peritoneal dialysis using rapid, small-volume exchanges. Am Soc Artif Intern Organs J 1979;2: 103-6.
61. Gotch F, Schoenfeld P, Gentile D. The peritoneal equilibration test (PET) is not a realistic measure of peritoneal clearance (PC) [abstract]. J Am Soc Nephrol 1991;2:361.